Articles Published in 2013

Imprimis acquires intellectual property from Novel Drug Solutions, Eye Care Northwest

Wednesday, August 28, 2013 12:32 PM

Imprimis Pharmaceuticals, focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships, has acquired intellectual property from Novel Drug Solutions and Eye Care Northwest, including a provisional patent application related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation could affect the $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional intellectual property and drug development opportunities.

More... »

BARDA awards Novan $7.8 million contract

Tuesday, August 27, 2013 11:30 AM

The U.S. Department of Health and Human Services has entered into a contract with Novan, a clinical-stage drug development company focused on topical delivery of nitric oxide, to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. 

More... »

Chiesi Group to acquire Zymenex

Tuesday, August 27, 2013 10:30 AM

Chiesi Group, a European pharmaceutical company, has agreed to acquire Danish biopharmaceutical company Zymenex and its related group of companies, a biopharmaceutical group focused on R&D of biologic therapeutics for the treatment of rare and life threatening genetic diseases. Terms of the transaction were not disclosed.

More... »

PPD acquires Acurian

Tuesday, August 27, 2013 10:20 AM

Wilmington, N.C.-based CRO Pharmaceutical Product Development (PPD) has acquired Acurian, a provider of clinical trial patient enrollment and retention solutions for the life sciences industry. 

More... »

Curemark, VTT Molecular Sciences Institute collaborate

Tuesday, August 27, 2013 09:30 AM

Curemark, a drug R&D company focused on neurological disorders, has entered into a collaborative research agreement with the VTT Molecular Sciences Institute (MSI), an independent, nonprofit research institute in Berkeley, Calif.

More... »

MedImmune acquires Amplimmune

Monday, August 26, 2013 12:24 PM

AstraZeneca has announced that MedImmune, its global biologics R&D arm, has agreed to acquire Amplimmune, a privately-held, Maryland-based biologics company focused on developing novel therapeutics in cancer immunology.

More... »

Vince & Associates expands early phase gastrointestinal capabilities

Monday, August 26, 2013 12:20 PM

Vince & Associates Clinical Research, a provider of early phase clinical research services to the global biopharmaceutical industry, has expanded its capabilities in the gastrointestinal (GI) therapeutic area with the addition of a dedicated endoscopy suite at its Clinical Pharmacology Unit.

More... »

Cresset expands scientific team, relocates to Cambridge Cluster

Monday, August 26, 2013 12:19 PM

Cresset, a provider of chemistry software and services, has relocated near Cambridge Cluster, in Litlington, Cambridgeshire, which will serve as the company's global headquarters.

More... »

Immune Pharmaceuticals, EpiCept complete merger

Monday, August 26, 2013 12:15 PM

Immune Pharmaceuticals has completed its merger with EpiCept. The merger combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early-stage cancer program and its late-stage topical pain product, AmiKet.

More... »

Icon launches risk-based monitoring service

Monday, August 26, 2013 12:12 PM

Global CRO Icon has launched ICONIK Monitoring, the first in a series of new services that will leverage its ICONIK technology platform.

More... »